These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 29995248

  • 1. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment].
    Knoop M, Haller H, Menne J.
    Internist (Berl); 2018 Aug; 59(8):799-804. PubMed ID: 29995248
    [Abstract] [Full Text] [Related]

  • 2. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M, Go RS, Willrich MAV.
    J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
    [Abstract] [Full Text] [Related]

  • 3. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 4. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 6. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.
    Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT.
    Pediatr Nephrol; 2015 Jun; 30(6):1039-42. PubMed ID: 25752761
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [Abstract] [Full Text] [Related]

  • 8. Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.
    Kurihara S, Yamaguchi A, Sonoda K, Yamada Y, Harada M, Hashimoto K, Shimojo H, Ikeda Y, Kamijo Y.
    BMC Nephrol; 2024 Jul 15; 25(1):224. PubMed ID: 39009967
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.
    Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A.
    Transfus Apher Sci; 2016 Dec 15; 55(3):357-362. PubMed ID: 27742267
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
    Laurence J.
    Clin Adv Hematol Oncol; 2020 Apr 15; 18(4):221-230. PubMed ID: 32628650
    [Abstract] [Full Text] [Related]

  • 15. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
    Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.
    Pediatrics; 2014 Jun 15; 133(6):e1764-8. PubMed ID: 24843055
    [Abstract] [Full Text] [Related]

  • 16. De novo systemic atypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with a novel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report.
    Li D, Wang W, Chen R, Wen J, Zhang M.
    J Nephrol; 2022 Sep 15; 35(7):1895-1899. PubMed ID: 35852773
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.
    Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL.
    Clin Nephrol; 2015 Sep 15; 84(3):181-5. PubMed ID: 25816809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.